Gilead Sciences exporting remdesivir, CEO says

Washington (AFP) – The head of the maker of remdesivir, an anti-viral shown to reduce recovery times in COVID-19 patients, said Sunday the company has been exporting the drug and is making it available to patients in the United States through the US government.Gilead Sciences CEO Daniel O’Day said the company is donating its entire existing supply of the drug — 1.5 million vials, enough to treat 100,000 to 200,000 patients.”We have been exporting for clinical trials and for compassionate use thousands of treatment courses,” O’Day said on CBS’s “Face the Nation.” “And our collaboration with th…

Read More

HEDGE accordingly